Trial Information
Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients
Inclusion Criteria:
- Male and females older than 18 years.
- Undergoing supratentorial parenchyma resection surgery.
- Capable of collaborate on probes and explorations included in the study.
- Signature the written informed consent form.
Exclusion Criteria:
- Life expectancy less than 12 months due to the suspected histological type of tumour.
- Hypothalamic-pituitary axis illness.
- Presence of Melanoma previously.
- Glomerular filtration rate less than 60 mL/min.
- Thyroid or parathyroid glands pathology.
- Myasthenia gravis.
- Respiratory depression.
- Pregnancy or breastfeeding.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Outcome Measure:
Serum S100B protein
Outcome Time Frame:
2 hours after the end of the surgery
Safety Issue:
No
Principal Investigator
Neus Fabregas, MD PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Hospital Clinic of Barcelona
Authority:
Spain: Spanish Agency of Medicines
Study ID:
MAGNA
NCT ID:
NCT01601314
Start Date:
October 2012
Completion Date:
December 2014
Related Keywords:
- Seizures (Incl Subtypes)
- Brain Tumor
- Brain Neoplasms
- Seizures